In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deltagen Research Laboratories

Latest From Deltagen Research Laboratories

Cerep Moves Beyond Services

Can slow and steady win the drug-discovery race? France's Cerep prepares to find out, as it pushes past its fee-for-service start.

BioPharmaceutical Strategy

CombiChem Squeezes Through a Narrow Exit Door

CombiChem's acquisition by DuPont deal is, somewhat paradoxically, yet further proof of the difficulty that early-stage biotechs will have in finding Big Pharma buyers. Unless discovery biotechs are offering something specifically appropriate to a particular drug firm, even moderately valued acquisitions are unlikely exit opportunities.

BioPharmaceutical Business Strategies

Biotech: Making Money the Old-Fashioned Way

At the January 1999 Hambrecht & Quist meeting, investors were hearing a new message from biotechs: the Millennium-ization of the industry. Platform companies are promising to leverage their technologies much more aggressively for many more customers. They'll identify their assets, sell them, and sell them again.

BioPharmaceutical Strategy

Combinatorial Power

Riccardo Pigliucci, former CEO of Life Sciences International PLC and past president and COO of Perkin Elmer Corp. thinks he has found a model that will serve the small companies' needs to build value, keep up with technological innovation and create large enough operations to make Big pharma feel comfortable in dealing with them. Discovery Partners International is a sort of holding company for drug discovery tool companies. It has made its first investments in combinatorial chemistry company Irori and chemical library provider ChemRx.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals